Gerhard Ries
Founder & CEO @ kineo finance
Basel, Switzerland
Gerhard Ries is a Series A investor at kineo finance in Basel focused on Biotechnology and Medical. Dr. Gerhard Ries is co-founder of BioMedInvest/BioMedCredit and has a strong background in the pharmaceutical, biotechnology and consulting industry. Previously, Dr. Ries was Partner at InterPharmaLink, a management consulting company, specializing on product portfolio- and supply chain optimization for large Pharma organizations. He hasseveral years of working experience as project manager at McKinsey & Co. focusing on Pharma and Life Science companies. Dr. Ries was business development manager at Novartis responsible for licensing opportunities in the Biotech sector. Dr. Ries holds a M.S. and Ph.D. degree in Molecular Biology from the University of Basel and a diploma in Biotechnology from the Fachhochschule Weihenstephan. He has several years of research experience in the Pharma/Biotech sector gathered at Ciba Geigy, Boehringer Mannheim, Harvard Medical School and Max Planck-Institute for Biochemistry.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Gerhard Ries invests in
Stages Gerhard Ries invests in
Countries Gerhard Ries invests in
Investment Focus
Industry
- Biotechnology 6 (60%)
- Medical 4 (40%)
- Health Care 4 (40%)
- Therapeutics 3 (30%)
- Software 1 (10%)
Stage
- Series A 4 (40%)
- Series B 1 (10%)
- Funding Round 1 (10%)
- Post-IPO Equity 1 (10%)
Country
- Switzerland 3 (30%)
- Germany 2 (20%)
- United States 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kupando
|
Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity. | $11.5M / Series A / Mar 18, 2026 | |
|
Kupando
|
Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity. | $12.5M / Series A / Sep 26, 2022 | |
b-rayZ
|
b-rayZ is a spin-off of the University Hospital Zurich. Their team consists of professional radiologists, data scientists and physicians, with more than 15 years of work experience in medical imaging and radiology. They develop and provide predictive deep learning analytical tools and algorithms for the assessment of your personal medical images. | $4.1M / Series A / Jul 07, 2022 | |
Immunic Therapeutics
|
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | $11M / Series A / Sep 05, 2017 | |
|
Immunic Therapeutics
|
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | Series A / Feb 01, 2017 | |
|
Immunic Therapeutics
|
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | $19.2M / Series A / Sep 27, 2016 | |
Kuros Biosciences
|
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.Founded in 2000 as a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), Kuros has developed a pipeline of products based upon its proprietary technology platforms. These platforms were developed fromwork carried out at ETHZ, at the University of Zürich and at the California Institute of Technology (CalTech). In addition, in early 2017 Kuros acquired Xpand Biotechnology to gain access to its MagnetOs family of bone graft substitutes and the associated surface science technology.Kuros has attractive commercial prospects in key market segments as well as an EU hub for future clinical and distribution operations. The company is in transition to commercial stage with one product having marketing approval in the EU and US and further product expected to achieve EU approval this year. MagnetOs is approved for sale in the EU for orthopedic, spine and dental applications, and in the US for posterolateral spinal fusion. In addition, a putty formulation is being prepared for submission in the EU and the US in the second half of this year. Neuroseal, a novel biomaterial for dural sealing, is Kuros’ second product and currently under review for CE marking in the EU.Kuros has also assembled a pipeline of clinical stage programs in various stages of development and amassed significant clinical and preclinical data in a number of indications and applications primarily in the area of orthobiologics. The Company has enrolled over 600 patients in multinational clinical trials, and has generated promising safety and efficacy in a number of significant indications. | $15.4M / Post-IPO Equity / Aug 18, 2015 | |
leon nanodrugs
|
leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. | Series A / Jul 27, 2015 | |
Vaximm
|
Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinicaltrials in 2011. | $8.5M / Jan 12, 2011 | |
Affimed
|
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim toovercome the limitations and challenges faced by current immuno-oncology (I-O) therapies. | $32M / Series B / Apr 04, 2007 |
Co-Investors
About kineo finance
kineo finance is a globally active financing specialist for innovative technologies and equipment. Originally under the name of DiaMedCare, kineo provides tailor-made venture leasing and working capital solutions for companies which are starting the commercialisation of new products and services with a hardware component. kineo enables youngcompanies to offer their customers product/market-specific "equipment-as-a-service" solutions via pay-per-use, renting or subscription models. Backed by large institutional investors, kineo offers a broad industry network and know-how and actively supports high-growth companies to accelerate the market entry of their innovations.
kineo finance Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Gerhard Ries
Founder & CEO
|
|||
Kreske Nickelsen
Partner
|
|||
Christine Müller
Partner
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Gerhard Ries invest in?
Gerhard Ries invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Gerhard Ries last invest?
The most recent investment recorded for Gerhard Ries closed in Mar 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
